MTOR and breast cancer: Despite preclinical observations that PTEN loss of function is associated with the efficacy of mTOR inhibitors such as everolimus, PTEN mutations or low protein expression did not predict everolimus activity in patients with HR+/HER2− metastatic BC in the TAMRAD and Bolero-2 trials [31,32].